COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
Mayo Clinic Director of Clinical Virology Matthew J. Binnicker, PhD, explains when clinical laboratories should consider pooled testing for SARS-CoV-2.
To clear up any ambiguity, the EUA further clarifies that only one testing option is permitted under the initial EUA.
If the COVID-19 pandemic continues into 2021, then clinical laboratories can expect many new competitors for SARS-CoV-2 testing.
Federal collaboration with Abbott materializes into contract quickly after BinaxNOW COVID-19 Ag Card EUA announcement.
Pathologist Frederick (Fritz) Kiechle, MD, PhD, reviews two potential testing strategies associated with COVID-19 management.
With another change to CDC COVID-19 testing guidance, clinical laboratories may begin to see more fluctuations in test volumes because of potentially conflicting federal, state, and local testing guidance.
Mayo Clinic Director of Clinical Virology Matthew J. Binnicker, PhD, explains when clinical laboratories should consider pooled testing for SARS-CoV-2.
To clear up any ambiguity, the EUA further clarifies that only one testing option is permitted under the initial EUA.
If the COVID-19 pandemic continues into 2021, then clinical laboratories can expect many new competitors for SARS-CoV-2 testing.
Federal collaboration with Abbott materializes into contract quickly after BinaxNOW COVID-19 Ag Card EUA announcement.
Pathologist Frederick (Fritz) Kiechle, MD, PhD, reviews two potential testing strategies associated with COVID-19 management.
With another change to CDC COVID-19 testing guidance, clinical laboratories may begin to see more fluctuations in test volumes because of potentially conflicting federal, state, and local testing guidance.
